CDKN2B-AS1 |
|
CDKN2B antisense RNA 1
|
|
|
0.491 |
0.769 |
69
|
53 |
ABO |
P16442
|
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
|
Enzyme
|
|
0.427 |
0.885 |
61
|
54 |
TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
44
|
49 |
MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
38
|
56 |
CASC15 |
|
cancer susceptibility 15
|
|
|
0.603 |
0.577 |
35
|
41 |
CCDC26 |
Q8TAB7
|
CCDC26 long non-coding RNA
|
|
|
0.647 |
0.615 |
31
|
41 |
GBAP1 |
|
glucosylceramidase beta pseudogene 1
|
|
|
0.623 |
0.538 |
29
|
8 |
PVT1 |
|
Pvt1 oncogene
|
|
|
0.495 |
0.731 |
27
|
31 |
RTEL1-TNFRSF6B |
|
RTEL1-TNFRSF6B readthrough (NMD candidate)
|
|
|
0.682 |
0.385 |
26
|
14 |
PCAT1 |
|
prostate cancer associated transcript 1
|
|
|
0.575 |
0.615 |
24
|
59 |
HCP5 |
Q6MZN7
|
HLA complex P5
|
|
|
0.595 |
0.808 |
23
|
17 |
LINC01122 |
|
long intergenic non-protein coding RNA 1122
|
|
|
0.821 |
0.269 |
22
|
30 |
TEX41 |
|
testis expressed 41
|
|
|
0.743 |
0.269 |
22
|
32 |
MIR3936HG |
|
MIR3936 host gene
|
|
|
0.861 |
0.269 |
22
|
18 |
LINC00824 |
|
long intergenic non-protein coding RNA 824
|
|
|
0.695 |
0.346 |
22
|
13 |
CCDC162P |
|
coiled-coil domain containing 162, pseudogene
|
|
|
0.890 |
0.154 |
21
|
28 |
MAPT-AS1 |
|
MAPT antisense RNA 1
|
|
|
0.711 |
0.269 |
21
|
17 |
HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
20
|
24 |
HNF1A-AS1 |
|
HNF1A antisense RNA 1
|
|
|
0.621 |
0.538 |
20
|
13 |
BDNF-AS |
|
BDNF antisense RNA
|
|
|
0.638 |
0.538 |
20
|
23 |
LINC02210-CRHR1 |
P34998
|
LINC02210-CRHR1 readthrough
|
|
|
0.570 |
0.692 |
20
|
30 |
IGF2-AS |
Q6U949
|
IGF2 antisense RNA
|
|
|
0.612 |
0.615 |
19
|
7 |
LINC00299 |
Q6ZSB3
|
long intergenic non-protein coding RNA 299
|
|
|
0.743 |
0.346 |
19
|
16 |
LINC00461 |
|
long intergenic non-protein coding RNA 461
|
|
|
0.736 |
0.423 |
19
|
24 |